---

Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Elmukhtar Habas*, Ala Habas, Amnna Rayani, Kalifa Farfar, Eshark Habas, Jamal Alfitori, Mehdi Arrayes, Amla Habas, Abdel-Monem Badawi Yousif

Volume : 3, Issue : 1, Year : 2024

Article Page : 4-20

Suggest article by email

Abstract

Venous thromboembolism (VTE) is one of the life-threatening complications in cancer patients, the incidence of which is affected by the patient and malignancy-related variables. Location, type, therapeutic route, stage, grade, and non-supportive treatment of the cancer are the most important VTE risk factors. Patient age, ethnicity, and concomitant genetic or acquired comorbidities or thrombophilias are known risk factors for VTE in cancer. All high-risk cancer patients admitted to hospitals or treated as outpatients should receive VTE prophylaxis. Low molecular weight heparin is the main treatment for active malignant VTE. Vitamin K antagonists and non-Vitamin K-dependent oral anticoagulants are used in stable, non-bleeding cancer patients. Anticoagulation should be continued until the cancer is treated or at least controlled. Over the past two decades, randomized clinical and observational trials have improved the pathogenesis and therapeutic knowledge of VTE, but many challenges remain. The lack of an optimal primary prophylaxis method for inpatients and outpatients in oncology and the care of cancer-associated VTE in standard and high-bleeding risk groups are examples for which more clinical research on cancer-associated thrombosis is necessary to address these issues. In this review, we describe the pathogenesis, factors that increase the risk of VTE, and the comparison between the effectiveness of available anticoagulants in the treatment and prevention of VTE in cancer patients.

Keywords: Anticoagulation in malignancy, Cancer and direct oral anticoagulant, Low molecular weight heparin in malignancy, Venous thromboembolism in cancer, Vitamin K antagonist in cancer, Warfarin in malignancy

How to cite : Habas E, Habas A, Rayani A, Farfar K, Habas E, Alfitori J, Arrayes M, Habas A, Yousif A B, Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities. Yemen J Med 2024;3(1):4-20

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.